These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 16142882

  • 21. Early disease course and predictors of disability in juvenile rheumatoid arthritis and juvenile spondyloarthropathy: a 3 year prospective study.
    Selvaag AM, Lien G, Sørskaar D, Vinje O, Førre Ø, Flatø B.
    J Rheumatol; 2005 Jun; 32(6):1122-30. PubMed ID: 15940778
    [Abstract] [Full Text] [Related]

  • 22. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis.
    Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, Baumgartner SW, Giannini EH, Pediatric Rheumatology Collaborative Study Group.
    Arthritis Rheum; 2008 May; 58(5):1496-504. PubMed ID: 18438876
    [Abstract] [Full Text] [Related]

  • 23. Delayed clinical response in patients with juvenile idiopathic arthritis treated with etanercept.
    Otten MH, Prince FH, Twilt M, van Rossum MA, Armbrust W, Hoppenreijs EP, Kamphuis S, Koopman-Keemink Y, Wulffraat NM, Gorter SL, Ten Cate R, van Suijlekom-Smit LW.
    J Rheumatol; 2010 Mar; 37(3):665-7. PubMed ID: 20080910
    [Abstract] [Full Text] [Related]

  • 24. The German etanercept registry for treatment of juvenile idiopathic arthritis.
    Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, Hospach T, Huppertz HI, Keitzer R, Küster RM, Michels H, Moebius D, Rogalski B, Thon A, Paediatric Rheumatology Collaborative Group.
    Ann Rheum Dis; 2004 Dec; 63(12):1638-44. PubMed ID: 15115709
    [Abstract] [Full Text] [Related]

  • 25. [Methotrexate treatment in refractory juvenile rheumatoid arthritis].
    Brik R.
    Harefuah; 1998 Dec 01; 135(11):509-11, 567. PubMed ID: 10911466
    [Abstract] [Full Text] [Related]

  • 26. [Efficacy of etanercept in the treatment of juvenile idiopathic arthritis].
    de Inocencio Arocena J, Merino Muñoz R, Alvarez Madrid C, García-Consuegra Molina J.
    An Pediatr (Barc); 2009 Apr 01; 70(4):354-61. PubMed ID: 19324597
    [Abstract] [Full Text] [Related]

  • 27. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.
    Baraliakos X, Brandt J, Listing J, Haibel H, Sörensen H, Rudwaleit M, Sieper J, Braun J.
    Arthritis Rheum; 2005 Dec 15; 53(6):856-63. PubMed ID: 16342093
    [Abstract] [Full Text] [Related]

  • 28. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
    Tynjälä P, Vähäsalo P, Honkanen V, Lahdenne P.
    Ann Rheum Dis; 2009 Apr 15; 68(4):552-7. PubMed ID: 18467515
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL, Symmons DP, Watson KD, Silman AJ, British Society for Rheumatology Biologics Register.
    Arthritis Rheum; 2006 Jun 15; 54(6):1786-94. PubMed ID: 16736520
    [Abstract] [Full Text] [Related]

  • 32. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate.
    Alsufyani K, Ortiz-Alvarez O, Cabral DA, Tucker LB, Petty RE, Malleson PN.
    J Rheumatol; 2004 Jan 15; 31(1):179-82. PubMed ID: 14705239
    [Abstract] [Full Text] [Related]

  • 33. The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis.
    Anandarajah AP, Schwarz EM, Totterman S, Monu J, Feng CY, Shao T, Haas-Smith SA, Ritchlin CT.
    Ann Rheum Dis; 2008 Mar 15; 67(3):296-301. PubMed ID: 17967829
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Patterns of joint involvement at onset differentiate oligoarticular juvenile psoriatic arthritis from pauciarticular juvenile rheumatoid arthritis.
    Huemer C, Malleson PN, Cabral DA, Huemer M, Falger J, Zidek T, Petty RE.
    J Rheumatol; 2002 Jul 15; 29(7):1531-5. PubMed ID: 12136915
    [Abstract] [Full Text] [Related]

  • 36. Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA.
    Keystone E, Freundlich B, Schiff M, Li J, Hooper M.
    J Rheumatol; 2009 Mar 15; 36(3):522-31. PubMed ID: 19228659
    [Abstract] [Full Text] [Related]

  • 37. Estimates of the discriminant ability of definitions of improvement for juvenile rheumatoid arthritis.
    Moroldo MB, Giannini EH.
    J Rheumatol; 1998 May 15; 25(5):986-9. PubMed ID: 9598903
    [Abstract] [Full Text] [Related]

  • 38. Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis.
    Billiau AD, Loop M, Le PQ, Berthet F, Philippet P, Kasran A, Wouters CH.
    Rheumatology (Oxford); 2010 Aug 15; 49(8):1550-8. PubMed ID: 20444859
    [Abstract] [Full Text] [Related]

  • 39. Clinical assessment and core outcome variables are poor predictors of hip arthritis diagnosed by MRI in juvenile idiopathic arthritis.
    Nistala K, Babar J, Johnson K, Campbell-Stokes P, Foster K, Ryder C, McDonagh JE.
    Rheumatology (Oxford); 2007 Apr 15; 46(4):699-702. PubMed ID: 17158211
    [Abstract] [Full Text] [Related]

  • 40. Clinical response to etanercept in polyarticular course juvenile rheumatoid arthritis.
    Kietz DA, Pepmueller PH, Moore TL.
    J Rheumatol; 2001 Feb 15; 28(2):360-2. PubMed ID: 11246677
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.